Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Oncol.

Sec. Cancer Molecular Targets and Therapeutics

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1588950

This article is part of the Research TopicRenewed Insight into Cancer Mechanism and TherapyView all 37 articles

Case Report: Dramatic Response to Entritinib in a Patient with Gastrointestinal Stromal Tumor Positive for NTRK3 fusion

Provisionally accepted
Guomin DongGuomin Dong1Pengyu HanPengyu Han1Zhiyun ZhangZhiyun Zhang1Qian GeQian Ge2Jian JiangJian Jiang1Suoni LiSuoni Li3Jiequn MaJiequn Ma3Jie BaiJie Bai3Hui WeiHui Wei1*Zheng ZhaoZheng Zhao3*
  • 1Shaanxi University of Chinese Medicine, Xianyang, China
  • 2Shaanxi Provincial People's Hospital, Xi'an, Shaanxi Province, China
  • 3Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi Province, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Gastrointestinal stromal tumor (GIST), the most common mesenchymal malignancy of the gastrointestinal tract, has been classified into five major molecularly subtypes through next-generation sequencing (NGS) including classical KIT/PDGFRA-mutant, SDH-deficient, NF1-assoicated, BRAF-mutant, and NTRK3-fusion GISTs [1]. Notably, the NTRK3 fusion have emerged as rare but clinically significant molecular alternations defining a distinct subgroup of GISTs[2]. Therefore, elucidating the clinicopathological characteristics, diagnostic approaches, and therapeutic implications regarding NTRK3 rearrangements hold critical value for advancing precision oncology. Herein, we present a case of a 60-year-old female diagnosed with an NTRK3 fusion, following we also include a comprehensive review of the current literature regarding this rare molecular entity.

Keywords: Gastrointestinal Stromal Tumor, acquired resistance, Next-generation sequencing, NTRK3 fusion, ctDNA dynamics predict

Received: 06 Mar 2025; Accepted: 24 Jul 2025.

Copyright: © 2025 Dong, Han, Zhang, Ge, Jiang, Li, Ma, Bai, Wei and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Hui Wei, Shaanxi University of Chinese Medicine, Xianyang, China
Zheng Zhao, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material